Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more
Market Cap & Net Worth: Indivior PLC (INDV)
Indivior PLC (LSE:INDV) has a market capitalization of $18.79 Million (GBX154.47 Billion) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #39594 globally and #560 in its home market, demonstrating a 8.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Indivior PLC's stock price GBX1238.00 by its total outstanding shares 124770000 (124.77 Million).
Indivior PLC Market Cap History: 2015 to 2025
Indivior PLC's market capitalization history from 2015 to 2025. Data shows growth from $13.78 Million to $18.79 Million (1.92% CAGR).
Index Memberships
Indivior PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$49.37 Million | 0.38% | #37 of 573 |
|
FTSE 350
FTLC
|
$42.79 Million | 0.44% | #35 of 350 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$187.94K | 100.00% | #1 of 6 |
Weight: Indivior PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Indivior PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Indivior PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Indivior PLC's market cap is 0.01 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.77x
Indivior PLC's market cap is 7.77 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $13.78 Million | $1.01 Billion | $228.00 Million | 0.01x | 0.06x |
| 2016 | $22.48 Million | $1.06 Billion | $35.00 Million | 0.02x | 0.64x |
| 2017 | $30.98 Million | $1.09 Billion | $58.00 Million | 0.03x | 0.53x |
| 2018 | $8.53 Million | $1.00 Billion | $275.00 Million | 0.01x | 0.03x |
| 2019 | $2.96 Million | $785.00 Million | $134.00 Million | 0.00x | 0.02x |
| 2020 | $8.26 Million | $647.00 Million | -$148.00 Million | 0.01x | N/A |
| 2021 | $19.51 Million | $791.00 Million | $205.00 Million | 0.02x | 0.10x |
| 2022 | $28.12 Million | $901.00 Million | -$53.00 Million | 0.03x | N/A |
| 2023 | $17.99 Million | $1.09 Billion | $2.00 Million | 0.02x | 8.99x |
| 2024 | $15.55 Million | $1.19 Billion | $2.00 Million | 0.01x | 7.77x |
Competitor Companies of INDV by Market Capitalization
Companies near Indivior PLC in the global market cap rankings as of March 18, 2026.
Key companies related to Indivior PLC by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Indivior PLC Historical Marketcap From 2015 to 2025
Between 2015 and today, Indivior PLC's market cap moved from $13.78 Million to $ 18.79 Million, with a yearly change of 1.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX18.79 Million | +20.90% |
| 2024 | GBX15.55 Million | -13.59% |
| 2023 | GBX17.99 Million | -36.02% |
| 2022 | GBX28.12 Million | +44.12% |
| 2021 | GBX19.51 Million | +136.21% |
| 2020 | GBX8.26 Million | +178.97% |
| 2019 | GBX2.96 Million | -65.29% |
| 2018 | GBX8.53 Million | -72.48% |
| 2017 | GBX30.98 Million | +37.81% |
| 2016 | GBX22.48 Million | +63.19% |
| 2015 | GBX13.78 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Indivior PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.79 Million USD |
| MoneyControl | $18.79 Million USD |
| MarketWatch | $18.79 Million USD |
| marketcap.company | $18.79 Million USD |
| Reuters | $18.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.